Memorial Sloan Kettering Cancer Center

Aimee Crago

Samuel Singer

Marta Kovatcheva

Andrew C Koff

Gary K Schwartz

William D Tap

Andrew Koff

Mary Elizabeth Dooley

David Liu

Mark A Dickson

Mary Elizabeth Klein

Andrew W Koff

The present disclosure relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present disclosure provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.

Enigma and CDH18 as companion diagnostics for CDK4 inhibitors

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.

Companion diagnostic for CDK4 inhibitors

Growing community of inventors

New York, NY, United States of America

Aimee Crago